slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
214,261-214,290 of 319,975
32
Data presented as mean change from baseline with 90% CI. Includes table of mean values for delta QTc and absolute QTc.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
33
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
34
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
35
The slide uses a complex biological pathway diagram to illustrate the mechanism of action and the problem of redundant signaling pathways.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
36
The slide presents two charts: a tumor growth inhibition curve and a PK/PD correlation chart showing drug concentration vs. target degradation over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
37
The slide outlines a standard oncology dose-escalation study design (3+3 or similar) followed by expansion cohorts.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
38
The slide presents clinical trial data for a drug candidate, comparing PK profiles across four dose levels (DL1-DL4).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
39
The slide presents longitudinal pharmacodynamic (PD) data for three targets across four dose levels, comparing clinical results to preclinical expectations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
40
The slide uses a split-layout to contrast clinical data findings with the strategic clinical development plan.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
41
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
42
Includes a table of prevalence/incidence data and a biological pathway diagram.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
43
The slide presents two charts: a tumor volume growth curve over time and a PK/PD profile showing drug concentration and target knockdown over 240 hours.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
44
The slide outlines a standard oncology clinical trial design (3+3 or similar dose escalation) followed by cohort expansion.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
45
Clinical trial safety data presentation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
46
Includes a line chart for PK profiles and a table for PK parameters (Cmax, AUClast, Vd, CL, t1/2).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
47
Includes a line chart showing % change over time and a summary table of patient-level degradation data.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
48
Includes bar charts for SAA/CRP, a longitudinal line chart for SOCS3, and a scatter plot showing correlation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
49
Data cut-off date May 1, 2023. DL1-3 completed, DL4 open.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
50
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
51
Includes a DepMap CRISPR sensitivity chart and a biological process diagram showing the MDM2-p53 feedback loop.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
52
The slide uses a biological pathway diagram to illustrate the mechanism of action and Western blot data to validate the claim.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
53
Includes a table comparing clinical stage and potency metrics (IC50, DC50) across multiple competitors.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
54
Data presented as tumor volume growth curves and Kaplan-Meier survival plots.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
55
The slide uses a series of bar charts to demonstrate the mechanism of action of the drug candidate KT-253 compared to vehicle and DS-3032.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
56
Shows two distinct experiments: DFAM-68555 (leukemia burden) and MOLM-13 (tumor volume).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
57
The slide title mentions KT-333, but the content refers to KT-253 throughout; this is likely a typo in the source slide.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
58
The slide uses a split-layout to contrast mechanism benefits (left) with strategic market opportunity (right).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
59
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Action1 hit
60
The slide serves as a standard closing/contact slide, featuring a high-impact photo of the company team at Nasdaq.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Action1 hit
01
Lakeland Bancorp | Investor Conference Presentation Deck | 19 slidesLakeland Bancorp | Investor Conference Presentation Deck | 19 slides · Lakeland
Conference presentation Investor relations Beat · Setup1 hit